Crescent Competitors

Stocks . USA . 
Stock . Crescent Biopharma
CBIO Stock  USD 11.75  1.05  8.20%   
Crescent Biopharma competes with Compugen, C4 Therapeutics, Sangamo Therapeutics, Insight Molecular, and Armata Pharmaceuticals; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Crescent Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Crescent Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Crescent Biopharma Correlation with its peers.
To learn how to invest in Crescent Stock, please use our How to Invest in Crescent Biopharma guide.

Crescent Biopharma vs OmniAb Correlation

Significant diversification

The correlation between Crescent Biopharma and OABI is 0.08 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Crescent Biopharma and OABI in the same portfolio, assuming nothing else is changed.

Moving against Crescent Stock

  0.62GE GE AerospacePairCorr
  0.6DIS Walt DisneyPairCorr
  0.58SLF Sun Life FinancialPairCorr
  0.47BA Boeing Earnings Call TodayPairCorr
  0.37BAC Bank of AmericaPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
7.6711.7515.83
Details
Intrinsic
Valuation
LowRealHigh
6.3410.4214.50
Details
Naive
Forecast
LowNextHigh
9.7013.7817.85
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
10.1412.0513.96
Details

Crescent Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Crescent Biopharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Crescent and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Crescent Biopharma does not affect the price movement of the other competitor.

High positive correlations

IPHA
+ 0.77
SGMO
HIND
+ 0.69
CCCC
OABI
+ 0.6
HRTX
HRTX
+ 0.55
CGEN
ARMP
+ 0.4
IMDX
IMDX
+ 0.32
CGEN
  

High negative correlations

HRTX
- 0.71
HIND
OABI
- 0.48
HIND
OABI
- 0.48
SGMO
HIND
- 0.46
CGEN
OABI
- 0.45
IPHA
ARMP
- 0.43
SGMO

Risk-Adjusted Indicators

There is a big difference between Crescent Stock performing well and Crescent Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Crescent Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Crescent Biopharma Competitive Analysis

The better you understand Crescent Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Crescent Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Crescent Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CBIO CGEN CCCC SGMO IMDX ARMP HIND HRTX IPHA OABI
 8.20 
 11.75 
Crescent
 2.87 
 2.03 
Compugen
 3.72 
 2.07 
CCCC
 5.00 
 0.38 
Sangamo
 0.77 
 6.57 
Insight
 2.00 
 6.12 
Armata
 9.25 
 3.19 
Vyome
 1.41 
 1.44 
Heron
 1.68 
 1.76 
Innate
 0.51 
 1.95 
OmniAb
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Very risky
Very risky
Out of control
Relatively risky
Risky
Very risky
Dangerous
Dangerous
Very risky
Market Performance
(90 Days Performance)
Weakest
Mild
Weakest
Weakest
Soft
Mild
Weakest
Fair
Weakest
Fair
Odds of Financial Distress
(Probability Of Bankruptcy)
Fair
Low
High
Risky
Risky
Strong
High
Strong
Risky
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Not Available
Not Available
Not Available
Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
18.86
6.16
6.9
2.86
N/A
5.59
N/A
1.77
2.34
0.57
Net Asset
28.44 M
115 M
349.6 M
101.64 M
35.08 M
86.44 M
4.79 M
233.15 M
111.06 M
325.56 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.0876
N/A
N/A
EBITDA
(52.15 M)
(14.4 M)
(103.37 M)
(89.09 M)
(59.02 M)
(41.11 M)
(6.65 M)
(5.06 M)
(46.91 M)
(50.92 M)
Current Valuation
287.81 M
106.53 M
77.94 M
123.47 M
54.24 M
381.37 M
34.39 M
353.19 M
130.17 M
243.72 M
Operating Margin
N/A
-4.17
-2.11
-61.19
-2.73
-6.71
-6.49
-0.11
-5.23
-8.1
Price To Book
N/A
4.33
1.35
20.45
8.0
2.11
N/A
37.07
27.74
1.02
Retained Earnings
(410.94 M)
(488.76 M)
(633.7 M)
(1.5 B)
(350.54 M)
(327.74 M)
(642.7 M)
(1.92 B)
(386.36 M)
(101.4 M)
Current Asset
68.7 M
53.09 M
1 K
212.58 M
N/A
4.48 M
N/A
134.75 M
N/A
N/A
Beta
1.29
2.86
2.94
1.3
0.99
1.31
N/A
1.28
0.59
0.85
Number Of Employees
41
74
110
183
46
60
17
122
174
114
Shares Outstanding
19.5 M
93.54 M
96.91 M
336.49 M
28.6 M
36.41 M
5.49 M
183.36 M
93.71 M
143.96 M
Cash Flow From Operations
(33.1 M)
49.6 M
(65.16 M)
(67.14 M)
(20.71 M)
(37.55 M)
(4.43 M)
(22.53 M)
(6.9 M)
(39.66 M)
Total Debt
38 K
2.91 M
65.76 M
30.57 M
3.66 M
126.52 M
967 K
177.76 M
31 M
23.16 M
Return On Equity
N/A
-0.53
-0.6
-4.8
-4.29
-34.39
N/A
-24.09
-2.71
-0.22
Number Of Shares Shorted
794.63 K
1.19 M
7.28 M
21.16 M
163.2 K
144.35 K
75.16 K
34.05 M
242.46 K
6.03 M
Book Value Per Share
-0.78
0.47
2.08
0.019
0.36
-2.64
-27.14
0.038
0.0664
1.93
Return On Asset
N/A
-0.18
-0.23
-0.68
-0.22
-0.22
-0.43
0.0043
-0.26
-0.13
Current Liabilities
37.76 M
8.38 M
49 K
20.1 M
N/A
4.08 M
N/A
19.73 M
N/A
N/A
Total Asset
28.44 M
115 M
349.6 M
101.64 M
35.08 M
86.44 M
4.79 M
233.15 M
111.06 M
325.56 M
Debt To Equity
0.017
0.024
0.25
0.13
N/A
0.73
N/A
6.64
0.37
0.11
Target Price
22.0
5.8
9.86
3.25
5.42
12.0
15.0
4.5
5.75
7.33
Short Ratio
N/A
2.96
3.89
3.74
6.44
3.36
0.19
17.49
8.92
9.94
Shares Owned By Institutions
2.21
13.57
72.53
18.61
56.3
2.09
0.74
84.48
0.15
55.65
Market Capitalization
292.5 M
191.09 M
208.37 M
129.45 M
86.66 M
218.44 M
29.89 M
260.37 M
164.92 M
280.71 M
Price To Earning
-0.34
-4.86
N/A
-15.31
N/A
-1.64
N/A
-5.15
N/A
N/A
Price To Earnings To Growth
0.02
N/A
0.07
N/A
N/A
N/A
N/A
-0.18
N/A
N/A
Price To Sales
N/A
27.68
6.92
3.94
22.55
43.22
75.76
1.68
13.05
13.31
Net Income
(8.24 M)
(14.23 M)
(105.32 M)
(97.94 M)
(60.66 M)
(18.92 M)
(7.13 M)
(13.58 M)
(49.47 M)
(62.03 M)
Earnings Per Share
N/A
-0.3
-1.67
-0.45
-3.79
-1.66
-0.21
-0.09
-0.65
-0.59
Shares Owned By Insiders
0.12
2.02
7.19
2.23
22.03
69.12
43.33
0.66
N/A
12.75
Revenue
N/A
27.86 M
35.58 M
57.8 M
1.88 M
5.17 M
8.01 M
144.28 M
12.62 M
26.39 M
Working Capital
11.38 M
85.84 M
212.59 M
5.89 M
4.48 M
(36.94 M)
(6.31 M)
117.56 M
52.76 M
53.05 M
Cash And Equivalents
75.39 M
88.21 M
307.78 M
315.72 M
N/A
36.98 M
N/A
83.54 M
123.35 M
N/A
Cash Per Share
2.39
1.02
6.29
2.02
N/A
1.02
N/A
0.81
1.54
N/A
Gross Profit
N/A
513 K
(81.66 M)
(72.03 M)
2.09 M
(21.04 M)
278.5 K
102.78 M
(30.79 M)
20.8 M
Day Typical Price
12.03
2.04
2.1
0.38
6.5
6.06
3.12
1.43
1.76
1.96
Accumulation Distribution
23956.49
2525.35
30699.63
79428.69
886.03
2887.34
0.1
19486.1
16.81
12709.72
Market Facilitation Index
0.0
N/A
N/A
N/A
0.0
0.0
0.34
N/A
0.0
N/A
Daily Balance Of Power
(0.86)
(1.50)
(0.80)
(2.00)
0.2083
0.2105
0.7941
0.5
(3.00)
(0.17)
Period Momentum Indicator
(1.05)
(0.06)
(0.08)
(0.02)
0.05
0.12
0.27
0.02
(0.03)
(0.01)
Rate Of Daily Change
0.92
0.97
0.96
0.95
1.01
1.02
1.09
1.01
0.98
0.99
Day Median Price
12.17
2.05
2.12
0.39
6.46
6.04
3.08
1.43
1.77
1.96
Price Action Indicator
(0.95)
(0.05)
(0.09)
(0.01)
0.14
0.15
0.24
0.02
(0.02)
(0.01)
Relative Strength Index
46.4
58.52
43.97
38.47
51.54
50.95
39.8
57.47
45.47
54.43
Coefficient Of Variation
(19,634)
1398.7
(1,682)
(719.82)
2363.58
1228.45
(632.76)
879.62
(3,012)
1159.64
Mean Deviation
2.76
3.04
3.25
3.64
4.01
5.5
3.66
2.4
2.66
2.68
Jensen Alpha
(0.04)
0.227
(0.38)
(0.84)
0.0219
0.4718
(0.82)
0.281
(0.21)
0.1715
Total Risk Alpha
(0.42)
(0.12)
(0.70)
(1.15)
(0.28)
(0.12)
(1.26)
0.0442
(0.64)
(0.05)
Sortino Ratio
N/A
0.0633
N/A
N/A
0.027
0.0768
N/A
0.091
N/A
0.0773
Downside Variance
N/A
12.14
N/A
N/A
24.24
46.53
N/A
9.58
N/A
8.35
Standard Deviation
4.08
4.22
4.45
4.83
5.05
7.43
4.93
3.19
4.84
3.53
Kurtosis
1.98
1.96
2.01
1.45
(0.38)
0.7688
1.06
1.06
21.0
0.3295
Potential Upside
7.58
7.78
8.06
7.69
9.03
14.07
8.42
6.6
4.02
7.97
Treynor Ratio
(0.49)
0.3204
(0.18)
(0.31)
0.0795
0.3424
(1.59)
0.3496
(0.34)
0.1699
Maximum Drawdown
20.39
22.26
24.93
21.63
22.08
38.51
26.76
16.52
39.49
15.52
Variance
16.61
17.8
19.81
23.33
25.54
55.25
24.27
10.17
23.45
12.47
Market Risk Adjusted Performance
(0.48)
0.3304
(0.17)
(0.30)
0.0895
0.3524
(1.58)
0.3596
(0.33)
0.1799
Risk Adjusted Performance
0.0045
0.0607
(0.04)
(0.09)
0.0396
0.0687
(0.11)
0.0911
(0.02)
0.0712
Skewness
0.6288
1.07
0.8023
0.107
0.3981
0.1981
0.4007
0.4465
3.19
0.7679
Semi Deviation
N/A
3.05
N/A
N/A
4.64
6.43
N/A
2.47
N/A
2.55
Information Ratio
(0.02)
0.0523
(0.08)
(0.16)
0.0263
0.0705
(0.17)
0.0883
(0.05)
0.0633
Value At Risk
(6.58)
(5.00)
(7.00)
(6.98)
(6.67)
(9.16)
(7.77)
(4.31)
(5.21)
(5.16)
Expected Short fall
N/A
(4.01)
N/A
N/A
(4.03)
(6.00)
N/A
(3.18)
N/A
(3.58)
Downside Deviation
N/A
3.48
N/A
N/A
4.92
6.82
N/A
3.09
N/A
2.89
Semi Variance
N/A
9.28
N/A
N/A
21.52
41.41
N/A
6.11
N/A
6.5

Crescent Biopharma Competition Performance Charts

Five steps to successful analysis of Crescent Biopharma Competition

Crescent Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Crescent Biopharma in relation to its competition. Crescent Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Crescent Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Crescent Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Crescent Biopharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Crescent Biopharma position

In addition to having Crescent Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Casinos Thematic Idea Now

Casinos
Casinos Theme
Companies that are related to providing casino-type services across multiple geographical areas. The Casinos theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Casinos Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Crescent Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Crescent Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Crescent Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Crescent Biopharma Stock:
How To Invest In Crescent
Details
Is Crescent Stock a good investment?
Details
What is Crescent Biopharma's Net Worth?
Details
Top Sectors
View
Check out Crescent Biopharma Correlation with its peers.
To learn how to invest in Crescent Stock, please use our How to Invest in Crescent Biopharma guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crescent Biopharma. If investors know Crescent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crescent Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Crescent Biopharma is measured differently than its book value, which is the value of Crescent that is recorded on the company's balance sheet. Investors also form their own opinion of Crescent Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Crescent Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crescent Biopharma's market value can be influenced by many factors that don't directly affect Crescent Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Crescent Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Crescent Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crescent Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY